These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reply from the authors. Anaesthetic management during open and percutaneous irreversible electroporation. Nielsen K; Scheffer HJ; Vieveen JM; van den Tol P; Meijerink MR; Bouwman RA Br J Anaesth; 2015 Sep; 115(3):473-4. PubMed ID: 26269471 [No Abstract] [Full Text] [Related]
4. Anaesthetic management during open and percutaneous irreversible electroporation. Nielsen K; Scheffer HJ; Vieveen JM; van Tilborg AA; Meijer S; van Kuijk C; van den Tol MP; Meijerink MR; Bouwman RA Br J Anaesth; 2014 Dec; 113(6):985-92. PubMed ID: 25173767 [TBL] [Abstract][Full Text] [Related]
5. Practical details, confirmed safety and new targets. Picard J; Leen E Br J Anaesth; 2015 Sep; 115(3):472-3. PubMed ID: 26269470 [No Abstract] [Full Text] [Related]
6. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Ball C; Thomson KR; Kavnoudias H Anesth Analg; 2010 May; 110(5):1305-9. PubMed ID: 20142349 [TBL] [Abstract][Full Text] [Related]
7. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study). Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201 [TBL] [Abstract][Full Text] [Related]
8. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. Sugimoto K; Moriyasu F; Kobayashi Y; Saito K; Takeuchi H; Ogawa S; Ando M; Sano T; Mori T; Furuichi Y; Nakamura I Jpn J Radiol; 2015 Jul; 33(7):424-32. PubMed ID: 26032929 [TBL] [Abstract][Full Text] [Related]
9. Navigation Systems for Treatment Planning and Execution of Percutaneous Irreversible Electroporation. Fuhrmann I; Probst U; Wiggermann P; Beyer L Technol Cancer Res Treat; 2018 Jan; 17():1533033818791792. PubMed ID: 30071779 [TBL] [Abstract][Full Text] [Related]
10. The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma. Zeng J; Liu G; Li ZH; Yang Y; Fang G; Li RR; Xu KC; Niu L Technol Cancer Res Treat; 2017 Feb; 16(1):120-124. PubMed ID: 27837054 [TBL] [Abstract][Full Text] [Related]
11. Percutaneous irreversible electroporation of a renal tumor: Anesthetic management. de la Flor-Robledo M; Solís-Muñoz P; Sanjuán-Álvarez M; Abadal-Villayandre JM; Asensio-Merino F Rev Esp Anestesiol Reanim; 2016; 63(7):419-22. PubMed ID: 26874983 [TBL] [Abstract][Full Text] [Related]
12. Percutaneous Irreversible Electroporation of Unresectable Hilar Cholangiocarcinoma (Klatskin Tumor): A Case Report. Melenhorst MC; Scheffer HJ; Vroomen LG; Kazemier G; van den Tol MP; Meijerink MR Cardiovasc Intervent Radiol; 2016 Jan; 39(1):117-21. PubMed ID: 25994516 [TBL] [Abstract][Full Text] [Related]
13. Tissue ablation with irreversible electroporation. Davalos RV; Mir IL; Rubinsky B Ann Biomed Eng; 2005 Feb; 33(2):223-31. PubMed ID: 15771276 [TBL] [Abstract][Full Text] [Related]
14. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial). Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890 [TBL] [Abstract][Full Text] [Related]
15. Anatomically Realistic Simulations of Liver Ablation by Irreversible Electroporation: Impact of Blood Vessels on Ablation Volumes and Undertreatment. Qasrawi R; Silve L; Burdío F; Abdeen Z; Ivorra A Technol Cancer Res Treat; 2017 Dec; 16(6):783-792. PubMed ID: 28093955 [TBL] [Abstract][Full Text] [Related]
16. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966 [TBL] [Abstract][Full Text] [Related]
17. Percutaneous ablation therapy of hepatocellular carcinoma with irreversible electroporation: MRI findings. Granata V; Fusco R; Catalano O; Piccirillo M; De Bellis M; Izzo F; Petrillo A AJR Am J Roentgenol; 2015 May; 204(5):1000-7. PubMed ID: 25905934 [TBL] [Abstract][Full Text] [Related]
18. Technology of irreversible electroporation and review of its clinical data on liver cancers. Cohen EI; Field D; Lynskey GE; Kim AY Expert Rev Med Devices; 2018 Feb; 15(2):99-106. PubMed ID: 29307242 [TBL] [Abstract][Full Text] [Related]
19. Percutaneous Approach to Irreversible Electroporation of the Pancreas: Miami Protocol. Venkat S; Hosein PJ; Narayanan G Tech Vasc Interv Radiol; 2015 Sep; 18(3):153-8. PubMed ID: 26365545 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of a Modified Biopsy Needle for Irreversible Electroporation Ablation and Periprocedural Tissue Sampling. Wimmer T; Srimathveeravalli G; Silk M; Monette S; Gutta N; Maybody M; Erinjery JP; Coleman JA; Solomon SB; Sofocleous CT Technol Cancer Res Treat; 2016 Dec; 15(6):749-758. PubMed ID: 26443800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]